aml kim1
3:00 KOMET-001: targeting menin-KMT2A in AML
KOMET-001: targeting menin-KMT2A in AML
3:00
495 просмотров
3:50 Key AML Testing for Better Care: Understanding Prognosis and Treatment Choices
Key AML Testing for Better Care: Understanding Prognosis and Treatment Choices
3:50
40 просмотров
2:09 Kimmo Porkka | EHA 2018 | Precision medicine in AML
Kimmo Porkka | EHA 2018 | Precision medicine in AML
2:09
320 просмотров
1:41 The emerging role of menin inhibitors in the treatment of NPM1-mutated and KMT2A-rearranged R/R AML
The emerging role of menin inhibitors in the treatment of NPM1-mutated and KMT2A-rearranged R/R AML
1:41
479 просмотров
3:47 The role of the Pin1/PML/P53 axis in AML
The role of the Pin1/PML/P53 axis in AML
3:47
137 просмотров
2:48 AMELI-01: safety and efficacy of UCART123v1.2 in R/R AML
AMELI-01: safety and efficacy of UCART123v1.2 in R/R AML
2:48
69 просмотров
2:06 EVI1 alteration in AML: mechanisms, disease risk & potential targeting
EVI1 alteration in AML: mechanisms, disease risk & potential targeting
2:06
175 просмотров
0:45 Dr. Roboz on the QuANTUM-R Trial in AML
Dr. Roboz on the QuANTUM-R Trial in AML
0:45
223 просмотра
2:24 Menin Inhibitors are on the Horizon for NPM1 Mutated AML | Eytan Stein | ASH 2021 #AML
Menin Inhibitors are on the Horizon for NPM1 Mutated AML | Eytan Stein | ASH 2021 #AML
2:24
431 просмотр
3:26 What Is the AGILE Study? Research for AML Patients With the IDH1 Mutation
What Is the AGILE Study? Research for AML Patients With the IDH1 Mutation
3:26
21 просмотр
4:26 Emerging Targeted Agents in AML
Emerging Targeted Agents in AML
4:26
227 просмотров
7:11 First-in-human CLL1-CD33 compound CAR T-cells for AML
First-in-human CLL1-CD33 compound CAR T-cells for AML
7:11
595 просмотров
3:46 A Look at Lower Intensity Chemotherapy in Untreated AML
A Look at Lower Intensity Chemotherapy in Untreated AML
3:46
16 просмотров
1:59 How is an AML Treatment Approach Determined?
How is an AML Treatment Approach Determined?
1:59
28 просмотров
1:09 Aref Al-Kali, MD, discusses CPX 351 in older high-risk patients in AML
Aref Al-Kali, MD, discusses CPX 351 in older high-risk patients in AML
1:09
23 просмотра
1:24 Phase I study of CD123 NK cell engager SAR443579 in R/R AML, B-ALL or HR-MDS
Phase I study of CD123 NK cell engager SAR443579 in R/R AML, B-ALL or HR-MDS
1:24
299 просмотров
16:51 AMP 2019: Investigation of AML clonal architecture with mutational and immunophenotypic profiling
AMP 2019: Investigation of AML clonal architecture with mutational and immunophenotypic profiling
16:51
212 просмотров
3:00 How Does One’s Culture Impact AML Care?
How Does One’s Culture Impact AML Care?
3:00
10 просмотров